We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Paying the critic

2 December 2004 By Robert Cyran

A US fund shorted Merck after employing a researcher who played a key role in forcing its blockbuster painkiller to be withdrawn. The researcher didn’t reveal his potential conflict. But the hedge fund must have known about it. That’s dubious ethics.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)